» Articles » PMID: 34855844

Determinants of Tuberculosis Treatment Interruption Among Patients in Vihiga County, Kenya

Overview
Journal PLoS One
Date 2021 Dec 2
PMID 34855844
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Despite robust Tuberculosis (TB) program with effective chemotherapy and high coverage, treatment interruption remains a serious problem. Interrupting TB treatment means that patients remain infectious for longer time and are at risk of developing drug resistance and death. This study was conducted to identify and describe predictors of TB treatment interruption.

Methods: A cohort of 291 notified TB patients from 20 selected health facilities in Vihiga County were enrolled in to the study and followed up until the end of treatment. Patient characteristics that potentially predict treatment interruption were recorded during treatment initiation using structured questionnaires. Patients who interrupted treatment were traced and reasons for stoppage of treatment recorded. Kaplan Meier method was used to estimate probabilities of treatment interruption by patient characteristics and determine time intervals. The Log rank test for the equality of survival distributions analyzed significance of survival differences among categorical variables. For multivariable analysis, Cox proportional hazard model, was fitted to identify predictors of TB treatment interruption through calculation of hazard ratios with 95% Confidence Intervals (CIs). For variable analysis, statistical significance was set at P ≤ 0.05. Reasons for treatment interruption were categorized according to most recurrent behavioral or experiential characteristics.

Results: Participants' median age was 40 years (IQR = 32-53) and 72% were male. Of the 291 patients, 11% (n = 32) interrupted treatment. Incidences of treatment interruption significantly occurred during intensive phase of treatment. Independent predictors of treatment interruption included alcohol consumption (HR = 9.2, 95% CI; 2.6-32.5, p < 0.001), being female (HR = 5.01, 95% CI; 1.68-15.0, p = 0.004), having primary or lower education level (HR = 3.09, 95% CI; 1.13-8.49, p < 0.029) and having a treatment supporter (HR = 0.33, 95% CI; 0.14-0.76, p = 0.009). Reasons for interrupting treatment were categorized as: alcoholism, feeling better after treatment initiation, associated TB stigma, long distance to health facility, lack of food, perception of not having TB and pill burden.

Conclusion: TB treatment interruption was high and largely associated with patients' socio-demographic and behavioral characteristics. These multidimensional factors suggest the need for interventions that not only target individual patients but also environment in which they live and receive healthcare services.

Citing Articles

Lived experiences of persons on tuberculosis treatment in Nairobi County, Kenya: a mixed methods study.

Ondiro J, Onyangore F, Onyango R, Muema L, Omondi Aduda D BMC Public Health. 2024; 24(1):3440.

PMID: 39696085 PMC: 11654145. DOI: 10.1186/s12889-024-20748-7.


Determinants of an unfavorable treatment outcome among tuberculosis patients in the Jimma Zone, Southwest Ethiopia.

Ereso B, Sagbakken M, Gradmann C, Yimer S Sci Rep. 2024; 14(1):29281.

PMID: 39592639 PMC: 11599842. DOI: 10.1038/s41598-024-78084-0.


Incidence and predictors of treatment interruption among patients on anti-tuberculosis treatment in Nekemte public healthcare facilities, Oromia, Western Ethiopia.

Getachew R, Tolossa T, Teklemariam Z, Ayele A, Roba H Front Epidemiol. 2024; 3:1234865.

PMID: 38455888 PMC: 10910942. DOI: 10.3389/fepid.2023.1234865.


Development and validation of a prediction model for unsuccessful treatment outcomes in patients with multi-drug resistance tuberculosis.

Ma J, Zeng L, Ren F, Dang L, Luo H, Wu Y BMC Infect Dis. 2023; 23(1):289.

PMID: 37147607 PMC: 10161636. DOI: 10.1186/s12879-023-08193-0.


Treatment Outcomes and Risk Factors of Multidrug-Resistant Tuberculosis Patients in Xi'an China, a Retrospective Cohort Study.

Ma J, Zeng L, Ren F, Dang L, Luo H, Wu Y Infect Drug Resist. 2022; 15:4947-4957.

PMID: 36060236 PMC: 9438796. DOI: 10.2147/IDR.S376177.

References
1.
Floyd K, Glaziou P, Houben R, Sumner T, White R, Raviglione M . Global tuberculosis targets and milestones set for 2016-2035: definition and rationale. Int J Tuberc Lung Dis. 2018; 22(7):723-730. PMC: 6005124. DOI: 10.5588/ijtld.17.0835. View

2.
Muture B, Keraka M, Kimuu P, Kabiru E, Ombeka V, Oguya F . Factors associated with default from treatment among tuberculosis patients in Nairobi province, Kenya: a case control study. BMC Public Health. 2011; 11:696. PMC: 3224095. DOI: 10.1186/1471-2458-11-696. View

3.
Munro S, Lewin S, Smith H, Engel M, Fretheim A, Volmink J . Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med. 2007; 4(7):e238. PMC: 1925126. DOI: 10.1371/journal.pmed.0040238. View

4.
Nxumalo N, Gilson L, Goudge J, Tsofa B, Cleary S, Barasa E . Accountability mechanisms and the value of relationships: experiences of front-line managers at subnational level in Kenya and South Africa. BMJ Glob Health. 2018; 3(4):e000842. PMC: 6038841. DOI: 10.1136/bmjgh-2018-000842. View

5.
Talwar H, Talreja J, Samavati L . T7 Phage Display Library a Promising Strategy to Detect Tuberculosis Specific Biomarkers. Mycobact Dis. 2016; 6(2). PMC: 5111870. DOI: 10.4172/2161-1068.1000214. View